|
1) Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma, In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008. p. 252-3
|
|
|
|
|
2) Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol. 2000; 111: 826-34
|
|
|
|
|
3) Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol. 2008; 26: 3189-95
|
|
|
|
|
|
4) Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007; 109: 478-85
|
|
|
|
|
|
5) Gill S, Melosky B, Haley L, et al. Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. Am J Med. 2003; 114: 56-8
|
|
|
|
|
|
6) Asada N, Odawara J, Kimura S, et al. Use of random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc. 2007; 82: 1525-7
|
|
|
|
|
|
7) Matsue K, Asada N, Takeuchi M, et al. A clinicopathological study of 13 cases of intravascular lymphoma: experience in a single institution over a 9-yr period. Eur J Haematol. 2008; 80: 236-44
|
|
|
|
|
|
8) Le EN, Gerstenblith MR, Gelber AC, et al. The use of blind skin biopsy in the diagnosis of intravascular B-cell lymphoma. J Am Acad Dermatol. 2008; 59: 148-51
|
|
|
|
|
|
9) Kong YY, Dai B, Sheng WQ, et al. Intravascular large B-cell lymphoma with cutaneous manifestations: a clinicopathologic, immunophenotypic and molecular study of three cases. J Cutan Pathol. 2009; 36: 865-70
|
|
|
|
|
|
10) Feldmann R, Schierl M, Sittenthaler M, et al. Intravascular large B-cell lymphoma of the skin: typical clinical manifestations and a favourable response to rituximab-containing therapy. Dermatology. 2009; Epub ahead of print
|
|
|
|
|
|
11) Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007; 25: 571-8
|
|
|
|
|
|
12) Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-86
|
|
|
|
|
|
13) Hoshino A, Kawada E, Ukita T, et al. Usefulness of FDG-PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin. Am J Hematol. 2004; 76: 236-9
|
|
|
|
|
|
14) Odawara J, Asada N, Aoki T, et al. 18F-fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma. Br J Haematol. 2007; 136: 684
|
|
|
|
|
|
15) Kitanaka A, Kubota Y, Imataki O, et al. Intravascular large B-cell lymphoma with FDG accumulation in the lung lacking CT/(67)gallium scintigraphy abnormality. Hematol Oncol. 2009; 27: 46-9
|
|
|
|
|
|
16) Yago K, Yanagita S, Aono M, et al. Usefulness of FDG-PET/CT for the diagnosis of intravascular large B-cell lymphoma presenting with fever of unknown origin and renal dysfunction. Rinsho Ketsueki. 2009; 50: 499-502
|
|
|
|
|
17) Shimada K, Kosugi H, Shimada S, et al. Evaluation of organ involvement in intravascular large B-cell lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Int J Hematol. 2008; 88: 149-53
|
|
|
|
|
|
18) Domizio P, Hall PA, Cotter F, et al. Angiotropic large cell lymphoma (ALCL): morphological, immunohistochemical and genotypic studies with analysis of previous reports. Hematol Oncol. 1989; 7: 195-206
|
|
|
|
|
|
19) DiGiuseppe JA, Nelson WG, Seifter EJ, et al. Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol. 1994; 12: 2573-9
|
|
|
|
|
|
20) Ferreri AJ, Campo E, Ambrosetti A, et al. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol. 2004; 15: 1215-21
|
|
|
|
|
|
21) Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-42
|
|
|
|
|
|
22) Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-91
|
|
|
|
|
|
23) Shimada K, Kinoshita T, Naoe T, et al. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol. 2009; 10: 895-902
|
|
|
|
|
|
24) Ferreri AJ, Dognini GP, Bairey O, et al. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ʻWesternʼ patients with intravascular large B-cell lymphoma. Br J Haematol. 2008; 143: 253-7
|
|
|
|
|
|
25) Ferreri AJ, Dognini GP, Govi S, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma？ J Clin Oncol. 2008; 26: 5134-6; author reply 6-7
|
|
|
|
|